<?xml version="1.0" encoding="UTF-8"?>
<itemContainer xmlns="http://omeka.org/schemas/omeka-xml/v5" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://omeka.org/schemas/omeka-xml/v5 http://omeka.org/schemas/omeka-xml/v5/omeka-xml-5-0.xsd" uri="https://pedpalascnetlibrary.omeka.net/items/browse?tags=Goldsby+R&amp;output=omeka-xml" accessDate="2026-03-15T00:34:25-04:00">
  <miscellaneousContainer>
    <pagination>
      <pageNumber>1</pageNumber>
      <perPage>40</perPage>
      <totalResults>1</totalResults>
    </pagination>
  </miscellaneousContainer>
  <item itemId="10999" public="1" featured="1">
    <itemType itemTypeId="1">
      <name>Text</name>
      <description>A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.</description>
      <elementContainer>
        <element elementId="53">
          <name>Citation List Month</name>
          <description/>
          <elementTextContainer>
            <elementText elementTextId="57272">
              <text>November 2017 List</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="56">
          <name>URL Address</name>
          <description/>
          <elementTextContainer>
            <elementText elementTextId="57280">
              <text>http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;amp;CSC=Y&amp;amp;NEWS=N&amp;amp;PAGE=fulltext&amp;amp;D=emex&amp;amp;AN=618183528</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="57">
          <name>Notes</name>
          <description/>
          <elementTextContainer>
            <elementText elementTextId="57281">
              <text>&lt;p&gt;Using Smart Source Parsing&lt;br /&gt;(pp Date of Publication: 2017&lt;/p&gt;</text>
            </elementText>
          </elementTextContainer>
        </element>
      </elementContainer>
    </itemType>
    <elementSetContainer>
      <elementSet elementSetId="1">
        <name>Dublin Core</name>
        <description>The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.</description>
        <elementContainer>
          <element elementId="50">
            <name>Title</name>
            <description>A name given to the resource</description>
            <elementTextContainer>
              <elementText elementTextId="57273">
                <text>Late Effects of Treatment and Palliative Care</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="45">
            <name>Publisher</name>
            <description>An entity responsible for making the resource available</description>
            <elementTextContainer>
              <elementText elementTextId="57274">
                <text>Pediatric Oncology</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="40">
            <name>Date</name>
            <description>A point or period of time associated with an event in the lifecycle of the resource</description>
            <elementTextContainer>
              <elementText elementTextId="57275">
                <text>2017</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="49">
            <name>Subject</name>
            <description>The topic of the resource</description>
            <elementTextContainer>
              <elementText elementTextId="57276">
                <text>Central Nervous System Tumor; Palliative Therapy; 59-05-2 (methotrexate); 69-74-9 (cytarabine); 147-94-4 (cytarabine); 154-93-8 (carmustine); 7413-34-5 (methotrexate); 15475-56-6 (methotrexate); 15663-27-1 (cisplatin); 26035-31-4 (cisplatin); 96081-74-2 (cisplatin); Advance Care Planning; Appetite Disorder; Bone Density; Brain Tumor; Carmustine; Childhood Cancer Survivor; Cisplatin; Constipation; Corticosteroid; Cytarabine; Diarrhea; Dyspnea; Endocrine Disease; Fatigue; Genetic Polymorphism; Health Care Quality; Human; Incidence; Medical Decision Making; Medulloblastoma; Methotrexate; Morbidity; Mortality Rate; Nausea And Vomiting; Neuroectoderm Tumor; Neuropathic Pain; Neuropsychological Test; Pain Assessment; Patient Care; Phase 1 Clinical Trial (topic); Priority Journal; Psychosocial Disorder; Quality Of Life; Questionnaire; Radiation Injury; Respiration Depression; Seizure; Signal Transduction; Spasticity</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="39">
            <name>Creator</name>
            <description>An entity primarily responsible for making the resource</description>
            <elementTextContainer>
              <elementText elementTextId="57277">
                <text>Chang E; Goldsby R; Mueller S; Banerjee A</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="41">
            <name>Description</name>
            <description>An account of the resource</description>
            <elementTextContainer>
              <elementText elementTextId="57278">
                <text>Identifying late effects of treatment and integrating palliative care when appropriate are increasingly recognized as important elements of childhood tumor management. Patients with CNS tumors are at a high risk for mortality, and survivors have high morbidity rates related to the late effects of treatment. While intensified therapy has improved average 5-year survival in patients with pediatric brain tumors to 73 % (Ostrom et al. 2014) from less than 60 % in 1975-1979 (Linabery and Ross 2008), it has also increased the long-term consequences. Survivors may develop a spectrum of late effects ranging from subtle memory loss and cosmetic anomalies to severe neurological disabilities and recurrent neoplasms. While seemingly quite different, both palliative and late-effects care focus on improving quality of life for patients and need to be integrated into the overall care plan.</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="43">
            <name>Identifier</name>
            <description>An unambiguous reference to the resource within a given context</description>
            <elementTextContainer>
              <elementText elementTextId="57279">
                <text>10.1007/978-3-319-30789-3_17</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="47">
            <name>Rights</name>
            <description>Information about rights held in and over the resource</description>
            <elementTextContainer>
              <elementText elementTextId="57282">
                <text>Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).</text>
              </elementText>
            </elementTextContainer>
          </element>
        </elementContainer>
      </elementSet>
    </elementSetContainer>
    <tagContainer>
      <tag tagId="5448">
        <name>147-94-4 (cytarabine)</name>
      </tag>
      <tag tagId="5449">
        <name>154-93-8 (carmustine)</name>
      </tag>
      <tag tagId="5451">
        <name>15475-56-6 (methotrexate)</name>
      </tag>
      <tag tagId="5452">
        <name>15663-27-1 (cisplatin)</name>
      </tag>
      <tag tagId="3464">
        <name>2017</name>
      </tag>
      <tag tagId="5453">
        <name>26035-31-4 (cisplatin)</name>
      </tag>
      <tag tagId="5446">
        <name>59-05-2 (methotrexate)</name>
      </tag>
      <tag tagId="5447">
        <name>69-74-9 (cytarabine)</name>
      </tag>
      <tag tagId="5450">
        <name>7413-34-5 (methotrexate)</name>
      </tag>
      <tag tagId="5454">
        <name>96081-74-2 (cisplatin)</name>
      </tag>
      <tag tagId="48">
        <name>Advance Care Planning</name>
      </tag>
      <tag tagId="5455">
        <name>Appetite Disorder</name>
      </tag>
      <tag tagId="5481">
        <name>Banerjee A</name>
      </tag>
      <tag tagId="5456">
        <name>Bone Density</name>
      </tag>
      <tag tagId="5457">
        <name>Brain Tumor</name>
      </tag>
      <tag tagId="5458">
        <name>Carmustine</name>
      </tag>
      <tag tagId="4191">
        <name>Central Nervous System Tumor</name>
      </tag>
      <tag tagId="5478">
        <name>Chang E</name>
      </tag>
      <tag tagId="5459">
        <name>Childhood Cancer Survivor</name>
      </tag>
      <tag tagId="5460">
        <name>Cisplatin</name>
      </tag>
      <tag tagId="1061">
        <name>Constipation</name>
      </tag>
      <tag tagId="5461">
        <name>Corticosteroid</name>
      </tag>
      <tag tagId="5462">
        <name>Cytarabine</name>
      </tag>
      <tag tagId="4652">
        <name>Diarrhea</name>
      </tag>
      <tag tagId="4184">
        <name>Dyspnea</name>
      </tag>
      <tag tagId="5463">
        <name>Endocrine Disease</name>
      </tag>
      <tag tagId="5464">
        <name>Fatigue</name>
      </tag>
      <tag tagId="5465">
        <name>Genetic Polymorphism</name>
      </tag>
      <tag tagId="5479">
        <name>Goldsby R</name>
      </tag>
      <tag tagId="4211">
        <name>Health Care Quality</name>
      </tag>
      <tag tagId="2570">
        <name>Human</name>
      </tag>
      <tag tagId="3445">
        <name>Incidence</name>
      </tag>
      <tag tagId="3081">
        <name>Medical Decision Making</name>
      </tag>
      <tag tagId="5466">
        <name>Medulloblastoma</name>
      </tag>
      <tag tagId="5467">
        <name>Methotrexate</name>
      </tag>
      <tag tagId="5468">
        <name>Morbidity</name>
      </tag>
      <tag tagId="5469">
        <name>Mortality Rate</name>
      </tag>
      <tag tagId="5480">
        <name>Mueller S</name>
      </tag>
      <tag tagId="4381">
        <name>Nausea And Vomiting</name>
      </tag>
      <tag tagId="5470">
        <name>Neuroectoderm Tumor</name>
      </tag>
      <tag tagId="4561">
        <name>Neuropathic Pain</name>
      </tag>
      <tag tagId="5471">
        <name>Neuropsychological Test</name>
      </tag>
      <tag tagId="5417">
        <name>November 2017 List</name>
      </tag>
      <tag tagId="882">
        <name>Pain Assessment</name>
      </tag>
      <tag tagId="2618">
        <name>Palliative Therapy</name>
      </tag>
      <tag tagId="5472">
        <name>Patient Care</name>
      </tag>
      <tag tagId="374">
        <name>Pediatric Oncology</name>
      </tag>
      <tag tagId="5473">
        <name>Phase 1 Clinical Trial (topic)</name>
      </tag>
      <tag tagId="2920">
        <name>Priority Journal</name>
      </tag>
      <tag tagId="5474">
        <name>Psychosocial Disorder</name>
      </tag>
      <tag tagId="165">
        <name>Quality Of Life</name>
      </tag>
      <tag tagId="2620">
        <name>Questionnaire</name>
      </tag>
      <tag tagId="5475">
        <name>Radiation Injury</name>
      </tag>
      <tag tagId="5476">
        <name>Respiration Depression</name>
      </tag>
      <tag tagId="3418">
        <name>Seizure</name>
      </tag>
      <tag tagId="5477">
        <name>Signal Transduction</name>
      </tag>
      <tag tagId="4188">
        <name>Spasticity</name>
      </tag>
    </tagContainer>
  </item>
</itemContainer>
